136 related articles for article (PubMed ID: 34807348)
1. Serum irisin is a novel biomarker for bladder cancer detection.
Taken K; Aslan R; Eryilmaz R; Alp HH; Huyut Z; Dönmez Mİ
Int Urol Nephrol; 2022 Jan; 54(1):55-61. PubMed ID: 34807348
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic and prognostic roles of serum irisin in bladder cancer.
Esawy MM; Abdel-Samd KM
Curr Probl Cancer; 2020 Aug; 44(4):100529. PubMed ID: 32139156
[TBL] [Abstract][Full Text] [Related]
3. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics.
Provatopoulou X; Georgiou GP; Kalogera E; Kalles V; Matiatou MA; Papapanagiotou I; Sagkriotis A; Zografos GC; Gounaris A
BMC Cancer; 2015 Nov; 15():898. PubMed ID: 26560078
[TBL] [Abstract][Full Text] [Related]
4. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
5. Bladder Cancer-Specific Nuclear Matrix Proteins-4 May Be a Potential Biomarker for Non-Muscle-Invasive Bladder Cancer Detection.
Wang ZY; Li HY; Wang H; Chi Q; Liu Y; Li XM
Dis Markers; 2018; 2018():5609395. PubMed ID: 30275913
[TBL] [Abstract][Full Text] [Related]
6. Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study.
Aslan R; Alp HH; Eryılmaz R; Huyut Z; Sevim M; Araz Ş; Ertas K; Taken K
Asian Pac J Cancer Prev; 2020 Feb; 21(2):505-509. PubMed ID: 32102531
[TBL] [Abstract][Full Text] [Related]
7. Plasma microRNA profiles for bladder cancer detection.
Adam L; Wszolek MF; Liu CG; Jing W; Diao L; Zien A; Zhang JD; Jackson D; Dinney CP
Urol Oncol; 2013 Nov; 31(8):1701-8. PubMed ID: 22863868
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Utility of Serum Golgi Phosphoprotein 3 in Bladder Cancer Patients.
Lu J; Zhong F; Sun B; Wang C
Med Sci Monit; 2019 Sep; 25():6736-6741. PubMed ID: 31494662
[TBL] [Abstract][Full Text] [Related]
9. Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer.
Jiang X; Du L; Duan W; Wang R; Yan K; Wang L; Li J; Zheng G; Zhang X; Yang Y; Wang C
Oncotarget; 2016 Jun; 7(24):36733-36742. PubMed ID: 27167342
[TBL] [Abstract][Full Text] [Related]
10. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Arndt C; Barski D; Otto T; Gerullis H
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513851
[TBL] [Abstract][Full Text] [Related]
11. Serum periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder.
Matsumoto K; Ikeda M; Matsumoto T; Nagashio R; Nishimori T; Tomonaga T; Nomura F; Sato Y; Kitasato H; Iwamura M
Asian Pac J Cancer Prev; 2014; 15(22):9927-31. PubMed ID: 25520130
[TBL] [Abstract][Full Text] [Related]
12. Bladder cancer invasion predictability based on preoperative neutrophil-lymphocyte ratio.
Kaynar M; Yıldırım ME; Badem H; Caviş M; Tekinarslan E; Istanbulluoğlu MO; Karataş ÖF; Çimentepe E
Tumour Biol; 2014 Jul; 35(7):6601-5. PubMed ID: 24696263
[TBL] [Abstract][Full Text] [Related]
13. Higher Serum Endothelial-Specific Molecule-1 (ESM-1/Endocan) Levels are Associated with Poor Pathological Outcomes in Primary Bladder Cancer: A Non-randomized, Prospective, Case-Control Study.
Okucu E; Yucetas U; Karsiyakali N; Koseoglu H; Yucetas E; Erkan E; Kadihasanoglu M; Toktas MG
Arch Esp Urol; 2023 Mar; 76(2):132-138. PubMed ID: 37139618
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic biomarkers in non-muscle invasive bladder cancer.
Faiena I; Rosser CJ; Chamie K; Furuya H
World J Urol; 2019 Oct; 37(10):2009-2016. PubMed ID: 30467596
[TBL] [Abstract][Full Text] [Related]
15. The clinical and prognostic value of miR-9 gene expression in Tunisian patients with bladder cancer.
Setti Boubaker N; Cicchillitti L; Said R; Gurtner A; Ayed H; Blel A; Karray O; Essid MA; Gharbi M; Bouzouita A; Rammeh Rommeni S; Chebil M; Piaggio G; Ouerhani S
Mol Biol Rep; 2019 Oct; 46(5):4743-4750. PubMed ID: 31214962
[TBL] [Abstract][Full Text] [Related]
16. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?
Scheffer AR; Holdenrieder S; Kristiansen G; von Ruecker A; Müller SC; Ellinger J
World J Urol; 2014 Apr; 32(2):353-8. PubMed ID: 23266581
[TBL] [Abstract][Full Text] [Related]
17. The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer.
Altay DU; Keha EE; Karagüzel E; Menteşe A; Yaman SO; Alver A
Int Braz J Urol; 2018; 44(4):734-739. PubMed ID: 29522296
[TBL] [Abstract][Full Text] [Related]
18. Serum betatrophin and irisin levels in hepatocellular carcinoma.
Pazgan-Simon M; Zuwala-Jagiello J; Menzyk T; Bator M; Derra A; Lekstan A; Grzebyk E; Simon K; Kukla M
J Physiol Pharmacol; 2020 Feb; 71(1):. PubMed ID: 32554846
[TBL] [Abstract][Full Text] [Related]
19. Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer.
Mizutani Y; Katsuoka Y; Bonavida B
Int J Oncol; 2012 Apr; 40(4):1246-50. PubMed ID: 22218530
[TBL] [Abstract][Full Text] [Related]
20. A novel diagnostic tool for the detection of bladder cancer: Measurement of urinary high mobility group box-1.
Benlier N; Solakhan M; Yıldırım Z; Kaya V; Yıldırım ÖA; Orhan N; Çiçek H; Yıldırım M
Urol Oncol; 2020 Aug; 38(8):685.e11-685.e16. PubMed ID: 32312640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
